Focal
segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring
or sclerosis in the kidney. Scarring damages the limited number of glomeruli in
the initial stages. It is more common in males than in females, and is very
common in African American population.
FSGS can be
caused by many diseases like diabetes, sickle cell disease, and HIV infection.
It is categorized into two types; primary and secondary FSGS, and can be
treated using corticosteroids, ACE inhibitors, immunosuppressive drugs,
diuretics, and diet modification.
Request
to Get Free Sample Pages at:
Retrophin
Inc. is in the process of developing Sparsentan, with dual mechanism of action
that combines angiotensin receptor blockade with endothelin receptor blockade
for the treatment of FSGS. Some other companies in FSGS pipeline are Variant
Pharmaceuticals Inc. and ChemoCentryx Inc.
Make
Enquiry Before Buying the Report:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment